- Home
- VCYT
VCYT
Veracyte Inc.
as 02-21-2025 3:45pm EST
Upcoming Earnings Alert:
Get ready for potential market movements as Veracyte Inc. VCYT prepares to release earnings report on 24 Feb 2025.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | 2013 |
| Target Price: | $40.86 | AVG Volume (30 days): | 693.1K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.61 - $47.32 | Next Earning Date: | 02-24-2025 |
| Revenue: | $425,331,000 | Revenue Growth: | 23.95% |
| Revenue Growth (this year): | 25.25% | Revenue Growth (next year): | 9.99% |
Stock Insider Trading Activity of Veracyte Inc. (VCYT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| EASTHAM KARIN | VCYT | Director | Jan 2 '25 | Sell | $40.31 | 10,000 | $403,005.64 | 23,188 | |
| Stapley Marc | VCYT | Chief Executive Officer | Dec 13 '24 | Sell | $43.75 | 5,590 | $242,736.96 | 307,745 | |
| McGuire Annie | VCYT | SVP, General Counsel | Dec 4 '24 | Sell | $44.02 | 18,699 | $823,178.60 | 72,869 | |
| Febbo Phillip G. | VCYT | Chief Scientific & Med Officer | Dec 4 '24 | Sell | $44.09 | 3,934 | $173,447.31 | 82,414 | |
| Chambers Rebecca | VCYT | Chief Financial Officer | Dec 2 '24 | Sell | $43.23 | 7,000 | $302,621.90 | 114,037 | |
| Leite John | VCYT | Chief Commercial Officer-CLIA | Dec 2 '24 | Sell | $43.25 | 1,050 | $45,407.88 | 73,810 | |
| Wygant Jonathan | VCYT | VP, Chief Accounting Officer | Dec 2 '24 | Sell | $43.36 | 956 | $41,452.45 | 40,270 | |
| Wygant Jonathan | VCYT | VP, Chief Accounting Officer | Nov 27 '24 | Sell | $42.89 | 5,032 | $215,833.55 | 40,270 |
Latest Veracyte Inc. News
VCYT Breaking Stock News: Dive into VCYT Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
Simply Wall St.
2 days ago
High Growth Tech Stocks To Watch In February 2025
Business Wire
3 days ago
Veracyte to Participate in Upcoming Investor Conferences
Investor's Business Daily
8 days ago
Schrodinger Stock Scores IBD Rating Upgrade
Business Wire
8 days ago
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
Zacks
9 days ago
Best Momentum Stocks to Buy for February 13th
Business Wire
11 days ago
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
Business Wire
17 days ago
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
Compare VCYT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCYT Veracyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.